New Triple-Drug attack tested for tough liver cancer
NCT ID NCT06608940
Summary
This study aimed to test a new three-drug combination for people with advanced liver cancer that cannot be removed by surgery. The goal was to see if adding an experimental drug called BC3402 to two existing immunotherapy drugs could be safe and work better than the standard two-drug treatment. The trial was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATO CELLULAR CARCINOMA (HCC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Case Comprehensive Cancer Center Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, 44195, United States
Conditions
Explore the condition pages connected to this study.